Rates of Helicobacter pylori eradication using traditional clarithromycin-containing triple therapies have decreased because of increasing clarithromycin resistance. 1 Villoria et al. report the findings of a meta-analysis that compared the rates of H. pylori eradication using a twice-daily triple therapy regimen consisting of either a standarddose or a high-dose PPI plus clari thromycin and either amoxicillin or tinidazole administered for 7 days. 2 The authors included 6 studies and a total of 1,703 patients in their analysis. The mean intention-to-treat success rate was 74% (734 of 992 patients) with a standard -dose PPI, and improved to 82% (587 of 711 patients, 95% CI 78-84%) with a high-dose PPI. 2 The authors' conclusion that triple therapy regimens that contain a high-dose PPI are slightly more effective than regimens that contain a standard -dose PPI is consistent with another meta-analysis, which compared once-daily versus twice-daily PPI dosing in triple therapy. 3 Villoria et al. attributed the modest, and in our opinion probably clinically insignificant improvement, to enhanced acid suppression.
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The overall success of H. pylori eradication in the meta-analysis by Villoria and colleagues was poor, even with administration of a high-dose SUMMARY Empiric clarithromycin-containing triple therapies for eradication of Helicobacter pylori do not reliably produce a ≥80% success rate on an intention-to-treat basis. This lack of adequate treatment response is primarily because of clarithromycin resistance. This commentary discusses the findings of a meta-analysis by Villoria et al. that investigated whether a triple therapy containing a high-dose PPI and clarithromycin plus either amoxicillin or tinidazole improves the success rate of H. pylori eradication compared with a triple therapy that contains a standard-dose PPI. The mean intention-to-treat cure rates were greater in patients who used the high-dose PPI regimen compared with the standard-dose regimen (82% vs 74%, respectively). However, the actual cure rates of these studies were poor and the improvements were unlikely to be clinically significant. The prevalence of clarithromycin resistance in most of the world is such that clarithromycin-containing triple therapy should not be used empirically. Alternatives include sequential or concomitant therapy and bismuth-containing quadruple therapies.
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PPI. 2 Poor cure rates with triple therapy containing clarithromycin are largely because of clarithromycin resistance, which effectively transforms triple therapy into a dual therapy (e.g. PPI plus amoxicillin). The results noted in this metaanalysis are probably related mostly to the PPI plus amoxicillin component of the triple therapy. Triple therapy could, therefore, be envisioned as the simultaneous administration of two dual therapies-a PPI plus clari thromycin and a PPI plus amoxicillin or tinidazole. 1 If the eradication rate expected for a 7-day course of treatment with a PPI plus clarithromycin was approximately 80% for susceptible strains and 0% for clari thro mycinresistant strains, the outcomes would not be greatly influenced by PPI dose, particularly for clarithromycin-resistant strains. By contrast, the results of treatment with a PPI plus amoxicillin are markedly influenced by PPI dose and duration. We believe the success rate of H. pylori eradication using a dual therapy regimen that consists of a twice-daily standard-dose PPI plus amoxicillin for 7 days to be approximately 35%, increasing to approximately 50% with a 14-day regimen or with a double dose of PPI. resistant. 2 If this assumption is correct, the rate of successful H. pylori eradication would theoretically be the sum of patients cured by using PPI plus clarithromycin (assuming that 80% of these patients have clari thromycin-susceptible strains) and those cured by using PPI plus amoxicillin. Thus, if 80% of patients have clarithromycins usceptible strains and this value is multiplied by the eradication rate for clarithromycin-susceptible H. pylori (80%), 64% of patients should be cured. The amoxicillin component of the triple therapy would be beneficial to those patients who were not susceptible to the clarithromycin component (i.e. 36% of patients), and if this value is multiplied by the eradication rate achieved by using amoxicillin for 7 days (35%), an additional 12.6% of patients should be cured. H. pylori eradication would be expected, therefore, to cure a total of 76.6% of patients, and this percentage should increase to 82% if the eradication rate achieved by PPI plus amoxicillin was increased to 50% because of the increased PPI dose. 1 On the other hand, metronida zole and tinidazole are pH-independent antibiotics, and increasing the PPI dose would not be expected to offset the detrimental effects of clarithromycin resistance. Accordingly, no significant improvement was seen with adminis tration of a high-dose PPI versus a standard-dose PPI in combination therapy with tinidazole. 2 Villoria et al. noted that the improved treatment success in patients who received therapy with a high PPI dose might relate to findings that have shown an enhanced effectiveness of triple therapy in poor metabolizers of PPIs, and who achieve improved control of acidity. 2,4,5 Among users of triple therapy, the benefit of improved pH control is independent of clarithromycin resistancethat is, the benefits of acid inhibition affect the PPI plus amoxicillin component, which is consistent with the notion that replication-dependent antibiotics only effectively eradicate H. pylori between pH 6-8. 6 Cure rates with administration of triple therapy are, in fact, closely related to the degree of acid suppression and this fact is exemplified by studies that have demonstrated a 100% cure rate in patients who have maintained a pH >4 for ≥90% of a 24-day treatment regimen, irrespective of clarithromycin susceptibility status. 6, 7 The increased effectiveness of amoxicillin in patients who metabolize PPIs slowly suggests that eradication rates >90% should be obtainable by using optimal PPI and amoxicillin dosing. 6 Studies are needed, therefore, to identify the PPI dose and dosing interval that will reliably achieve pH control similar to that achieved in slow PPI metabolizers. Alternatively, long-acting PPIs or a combination of PPIs and antacids could be used, 8 which, theoretically, should produce cure rates that approach 100%, and thus reduce any contribution made by clarithromycin resistance. As treatment studies notoriously destroy new theoretical strategies for H. pylori eradication, only clinical trials performed within different populations and regions will determine whether these goals can be achieved. The meta-analysis by Villoria et al. demonstrates how to improve eradica tion rates slightly, but these cure rates are still clinically unacceptable. 2 The prevalence of clari thro mycin resistance in most of the world is such that empiric triple therapy should be replaced by alternative treatments such as sequential or concomitant therapy, or bismuthcontaining quad ruple therapies. In areas in which clarithromycin and metronidazole resistance is particularly preva lent, H. pylori treatment strategies that contain either of these antibiotics should be avoided. 1, 6 
